These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 31302695

  • 1. Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension.
    van Vollenhoven RF, Navarra SV, Levy RA, Thomas M, Heath A, Lustine T, Adamkovic A, Fettiplace J, Wang ML, Ji B, Roth D.
    Rheumatology (Oxford); 2020 Feb 01; 59(2):281-291. PubMed ID: 31302695
    [Abstract] [Full Text] [Related]

  • 2. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care.
    Bruce IN, Urowitz M, van Vollenhoven R, Aranow C, Fettiplace J, Oldham M, Wilson B, Molta C, Roth D, Gordon D.
    Lupus; 2016 Jun 01; 25(7):699-709. PubMed ID: 26936891
    [Abstract] [Full Text] [Related]

  • 3. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.
    Furie RA, Wallace DJ, Aranow C, Fettiplace J, Wilson B, Mistry P, Roth DA, Gordon D.
    Arthritis Rheumatol; 2018 Jun 01; 70(6):868-877. PubMed ID: 29409143
    [Abstract] [Full Text] [Related]

  • 4. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
    Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA, LBSL02/99 Study Group.
    J Rheumatol; 2014 Feb 01; 41(2):300-9. PubMed ID: 24187095
    [Abstract] [Full Text] [Related]

  • 5. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO, Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, Gordon D, Groark J, Henderson RB, Oldham M, Tak PP.
    BMJ Open; 2019 Mar 20; 9(3):e025687. PubMed ID: 30898822
    [Abstract] [Full Text] [Related]

  • 6. Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study.
    Urowitz MB, Ohsfeldt RL, Wielage RC, Dever JJ, Zakerifar M, Asukai Y, Ramachandran S, Joshi AV.
    Lupus Sci Med; 2020 Oct 20; 7(1):. PubMed ID: 33051264
    [Abstract] [Full Text] [Related]

  • 7. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.
    Doria A, Bass D, Schwarting A, Hammer A, Gordon D, Scheinberg M, Fox NL, Groark J, Stohl W, Kleoudis C, Roth D.
    Lupus; 2018 Aug 20; 27(9):1489-1498. PubMed ID: 29807477
    [Abstract] [Full Text] [Related]

  • 8. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus.
    Merrill JT, Ginzler EM, Wallace DJ, McKay JD, Lisse JR, Aranow C, Wellborne FR, Burnette M, Condemi J, Zhong ZJ, Pineda L, Klein J, Freimuth WW, LBSL02/99 Study Group.
    Arthritis Rheum; 2012 Oct 20; 64(10):3364-73. PubMed ID: 22674457
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
    Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, Kleoudis C, Groark J, Bass D, Fox NL, Roth D, Gordon D.
    Arthritis Rheumatol; 2017 May 20; 69(5):1016-1027. PubMed ID: 28118533
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
    Brunner HI, Abud-Mendoza C, Mori M, Pilkington CA, Syed R, Takei S, Viola DO, Furie RA, Navarra S, Zhang F, Bass DL, Eriksson G, Hammer AE, Ji BN, Okily M, Roth DA, Quasny H, Ruperto N.
    RMD Open; 2021 Sep 20; 7(3):. PubMed ID: 34531304
    [Abstract] [Full Text] [Related]

  • 11. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
    Tanaka Y, Bass D, Chu M, Egginton S, Ji B, Roth D.
    Mod Rheumatol; 2020 Mar 20; 30(2):313-320. PubMed ID: 31199180
    [Abstract] [Full Text] [Related]

  • 12. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
    Ginzler E, Guedes Barbosa LS, D'Cruz D, Furie R, Maksimowicz-McKinnon K, Oates J, Santiago MB, Saxena A, Sheikh S, Bass DL, Burriss SW, Gilbride JA, Groark JG, Miller M, Pierce A, Roth DA, Ji B.
    Arthritis Rheumatol; 2022 Jan 20; 74(1):112-123. PubMed ID: 34164944
    [Abstract] [Full Text] [Related]

  • 13. Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus.
    Schwarting A, Dooley MA, Roth DA, Edwards L, Thompson A, Wilson B.
    Lupus; 2016 Dec 20; 25(14):1587-1596. PubMed ID: 27488472
    [Abstract] [Full Text] [Related]

  • 14. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
    Zhang F, Bae SC, Bass D, Chu M, Egginton S, Gordon D, Roth DA, Zheng J, Tanaka Y.
    Ann Rheum Dis; 2018 Mar 20; 77(3):355-363. PubMed ID: 29295825
    [Abstract] [Full Text] [Related]

  • 15. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials.
    Strand V, Levy RA, Cervera R, Petri MA, Birch H, Freimuth WW, Zhong ZJ, Clarke AE, BLISS-52 and -76 Study Groups.
    Ann Rheum Dis; 2014 May 20; 73(5):838-44. PubMed ID: 23524886
    [Abstract] [Full Text] [Related]

  • 16. Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus.
    Wallace DJ, Ginzler EM, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Petri M, Fettiplace J, Roth DA, Ji B, Heath A.
    Arthritis Rheumatol; 2019 Jul 20; 71(7):1125-1134. PubMed ID: 30771238
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
    Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA, BLISS-52 Study Group.
    Lancet; 2011 Feb 26; 377(9767):721-31. PubMed ID: 21296403
    [Abstract] [Full Text] [Related]

  • 18. Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials.
    Abrahamowicz M, Esdaile JM, Ramsey-Goldman R, Simon LS, Strand V, Lipsky PE.
    Arthritis Rheumatol; 2018 Sep 26; 70(9):1450-1458. PubMed ID: 29648686
    [Abstract] [Full Text] [Related]

  • 19. Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment.
    Strand V, Berry P, Lin X, Asukai Y, Punwaney R, Ramachandran S.
    Arthritis Care Res (Hoboken); 2019 Jun 26; 71(6):829-838. PubMed ID: 30320964
    [Abstract] [Full Text] [Related]

  • 20. Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis.
    Urowitz MB, Ohsfeldt RL, Wielage RC, Kelton KA, Asukai Y, Ramachandran S.
    Ann Rheum Dis; 2019 Mar 26; 78(3):372-379. PubMed ID: 30610066
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.